| Literature DB >> 21261860 |
Adam C Fisher1, Jae-Young Kim, Ritsdeliz Perez-Rodriguez, Danielle Tullman-Ercek, Wallace R Fish, Lee A Henderson, Matthew P DeLisa.
Abstract
Historically, the general secretory (Sec) pathway of Gram-negative bacteria has served as the primary route by which heterologous proteins are delivered to the periplasm in numerous expression and engineering applications. Here we have systematically examined the twin-arginine translocation (Tat) pathway as an alternative, and possibly advantageous, secretion pathway for heterologous proteins. Overall, we found that: (i) export efficiency and periplasmic yield of a model substrate were affected by the composition of the Tat signal peptide, (ii) Tat substrates were correctly processed at their N-termini upon reaching the periplasm and (iii) proteins fused to maltose-binding protein (MBP) were reliably exported by the Tat system, but only when correctly folded; aberrantly folded MBP fusions were excluded by the Tat pathway's folding quality control feature. We also observed that Tat export yield was comparable to Sec for relatively small, well-folded proteins, higher relative to Sec for proteins that required cytoplasmic folding, and lower relative to Sec for larger, soluble fusion proteins. Interestingly, the specific activity of material purified from the periplasm was higher for certain Tat substrates relative to their Sec counterparts, suggesting that Tat expression can give rise to relatively pure and highly active proteins in one step.Entities:
Mesh:
Substances:
Year: 2008 PMID: 21261860 PMCID: PMC3057487 DOI: 10.1111/j.1751-7915.2008.00041.x
Source DB: PubMed Journal: Microb Biotechnol ISSN: 1751-7915 Impact factor: 5.813
Figure 1Schematic of expression constructs used in this study. Shown are the various chimeras generated for these studies along with the corresponding plasmid name (see Experimental procedures and Table 3 for more details). Dashed lines indicate cleavage site between native signal and mature domain for MBP and PhoA. POI includes one of the following: TrxA, GST, PhoA, GFP, Top7 and TraR. Drawing is not to scale.
Tat signal peptides that promote transport of MBP.
| Signal peptide | HS3018 | HS3018 Δ |
|---|---|---|
| AmiA | ++ | ++ |
| AmiC | ++ | ++ |
| ++ | − | |
| + | − | |
| + | − | |
| + | − | |
| FhuD | ++ | ++ |
| ++ | − | |
| HybA | + | + |
| HybO | + | + |
| + | − | |
| NapG | + | + |
| NrfC | + | + |
| ++ | − | |
| ++ | − | |
| TorA (KK) | − | − |
| TorZ | + | + |
| + | − | |
| YaeI | ++ | ++ |
| YahJ | + | + |
| + | − | |
| ++ | − | |
| ++ | − | |
| YdcG | ++ | ++ |
| ++ | − | |
| YedY | + | + |
| YfhG | + | + |
| ++ | − | |
| YnfF | + | + |
Expression of each ssTat–MBP construct was from pBAD18‐Cm (Tullman‐Ercek ).
++, bright red colonies, equivalent to malE+ cells streaked on MacConkey maltose agar plates; +, pale red colonies; −, white colonies; bold font, Tat specific.
Bacterial strains and plasmids used in this study.
| Strain or plasmid | Relevant genotype or features | Reference or source |
|---|---|---|
| MC4100 | F‐ | Laboratory stock |
| B1LK0 | MC4100 Δ | |
| HS3018 | MC4100 | |
| HS3018 Δ | HS3018 | |
| DHB4 | F′ | Laboratory stock |
| FÅ113 | DHB4 | |
| 959 | AMEF | |
| pTrc99A | Amersham Biosciences | |
| pMBP | Native MBP in pTrc99A | This study |
| pssTorA(+10)–MBP | ssTorA plus residues 1–10 of mature TorA fused to Δ(1–26)MBP in pTrc99A | This study |
| pssTorA(+6)–MBP | ssTorA plus residues 1–6 of mature TorA fused to Δ(1–26)MBP in pTrc99A | This study |
| pssTorA(+0)–MBP | ssTorA fused to Δ(1–26)MBP in pTrc99A | This study |
| pssTat–MBP | ssTat‐Δ(1–26)MBP in pBAD18‐Cm where ssTat is any putative | |
| pssTorA–PhoA | ssTorA‐Δ(1–22)PhoA in pTrc99A | |
| pPhoA | Native PhoA in pTrc99A | This study |
| pΔss‐PhoA | Δ(1–22)PhoA in pTrc99A | This study |
| pssTorA–scFv13.R4 | ssTorA fused to scFv13.R4 in pTrc99A | This study |
| pssMBP–scFv13.R4 | ssMBP fused to scFv13.R4 in pTrc99A | This study |
| pTMM | ssTorA fused to Δ(1–26)MBP with a mini MCS in between the signal and MBP, cloned in pTrc99A | This study |
| pssTorA–POI–MBP | ssTorA signal peptide–POI–Δ(1–26)MBP fusion in pTrc99A | This study |
| pssTorA–MBP–GFP | ssTorA‐Δ(1–26)MBP–GFP fusion in pTrc99A | This study |
| pMBP–GFP | Native MBP fused to GFP in pTrc99A | This study |
| pssTorA–MBP‐scFv13 | ssTorA‐Δ(1–26)MBP‐scFv13 in pTrc99A | This study |
| pssTorA–MBP–scFv13.R4 | ssTorA‐Δ(1–26)MBP–scFv13.R4 in pTrc99A | This study |
| pMBP–scFv13.R4 | Native MBP fused to scFv13.R4 in pTrc99A | This study |
Figure 2Intracellular localization, phenotype and yield of Tat‐targeted MBP. A. Western blot analysis of total soluble lysate (Lys), cytoplasmic (Cyt), periplasmic (Per) and insoluble (Ins) fractions from HS3018 (malE‐deficient derivative of MC4100) cells expressing wild‐type (wt) MBP and ssTorA–MBP with 0, 6 or 10 additional residues of mature TorA (+0, +6, +10). Western blots were probed with anti‐MBP primary antibody. B. HS3018 and HS3018 ΔtatC cells expressing the above constructs streaked on MacConkey agar media supplemented with 0.4% maltose. C. Yield of the above constructs following imac purification from the periplasm of HS3018 cells. Data represent the average of three replicate experiments. D. Amino acid sequence of the TorA (+10) signal peptide highlighting the primary signal peptidase cleavage site (white triangle) and the second cleavage site (grey triangle) as reported by N‐terminal sequencing.
Comparison of expression yields using the Tat or Sec export pathways.
| POI | Signal peptide | Yield (mg l−1) | Tat/Sec ratio (%) | Reference |
|---|---|---|---|---|
|
| ||||
| MBP | − | This study | ||
| TorA(+10) | 4.6 | 47 | This study | |
| TorA(+6) | 5.0 | 51 | This study | |
| TorA(+0) | 5.9 | 60 | This study | |
| GFP | nm | Nd | This study | |
| TorA | 10–15 | Nd | ||
| MBP–GFP | − | This study | ||
| TorA | 2.6 | 650 | This study | |
| scFv 26.10 | − | |||
| TorA | 0.1 | 12 | ||
| scFv13.R4 | − | This study | ||
| TorA | 0.06 | 600 | This study | |
| MBP–scFv13.R4 | − | This study | ||
| TorA | 0.5 | 6 | This study | |
| Human tPA (truncated) | − | |||
| TorA | 44.8 | 29 | ||
|
| ||||
| | nr | − | ||
| XlnC | nr | 33 | ||
| | nr | − | ||
| XlnC | nr | 70 | ||
| | − | |||
| XlnC | 0.1–0.2 | 4 | ||
| Human TNFa | − | |||
| XlnC | 1.6 | 7 | ||
| XyyZ | 1.4 | 6 | ||
| Human IL‐2 | − | |||
| XlnC | 4.8 | 46 | ||
All signal peptides derived from E. coliunless otherwise noted. Sec‐dependent signal peptides are listed in italics.
Tat/Sec ratio calculated by dividing yield measured for Tat expression by the value measured for Sec expression. All values represent yield obtained from periplasmic or supernatant fraction.
All proteins expressed in E. coliwere purified from the periplasm.
Yields obtained using high‐cell E. colidensity fermentations.
Expression via the Tat system was achieved using strain FÅ113 that has a more oxidizing cytoplasm than wild‐type strains of E. coli.
All proteins expressed in S. lividanswere secreted and purified from the medium.
Sec signal peptide derived from Streptomyces venezuelae xylanase B1 (XlnB1).
Tat‐dependent signal peptide derived from S lividansxylanase C (XlnC).
Signal peptide derived from S. venezuelaeCBS762.70 subtilisin inhibitor (Vsi).
Signal peptide derived from S lividans tyrosinase (XyyZ).
nd, not determined; nm, not measurable (protein is completely undetectable); nr, not reported.
Figure 3Intracellular localization and activity of ssTorA–PhoA. A. Western blot analysis of total soluble lysate (top panel) and cytoplasmic (cyt) and periplasmic (per) fractions (bottom panel) from FÅ113 cells expressing Tat‐targeted (ssTorA), Sec‐targeted (native) and cytoplasmic (Δss) PhoA and empty vector pTrc99A control cells. Western blots were probed with anti‐PhoA primary antibody. B. PhoA activity in the above cells and constructs assayed in both the cytoplasmic and periplasmic fractions. All data normalized to the activity measured for ssTorA–PhoA in the periplasmic fraction. Data represent the average of three replicate experiments.
Figure 4mRNA stability analysis of PhoA constructs. A. Predicted mRNA secondary structure and thermodynamic stability of sstorAtranscript using the mfold program (Zuker, 2003). B. Quantitative RT‐PCR analysis of mRNA isolated from FÅ113 cells expressing Tat‐targeted (ssTorA), Sec‐targeted (native) and cytoplasmic (Δss) PhoA. Grey bars indicate phoA levels while white bars correspond to 16s rRNA controls. Data for two different primer concentrations (0.5 and 9.0 µM) are shown and is the average of three replicate experiments.
Figure 5Intracellular localization and phenotype of Tat‐targeted MBP sandwich fusions. A. Western blot analysis of periplasmic (per; top panel) and cytoplasmic (cyt; bottom panel) fractions from HS3018 and HS3018 ΔtatC (lane 2 only) cells expressing ssTorA–MBP (lanes 1 and 2) and ssTorA–POI–MBP sandwich fusions of the following POIs: GST, PhoA, Top7, GFP, TrxA and TraR (lanes 3–8). Western blots were probed with anti‐MBP and anti‐GroEL primary antibody as indicated. GroEL was used to indicate the quality of each fractionation. B. Spot plating of cells and constructs described above on M9 minimal agar media supplemented with 0.4% maltose.
Figure 6Intracellular localization and activity of Tat‐targeted MBP–scFv fusions. A. Western blot analysis of periplasmic (per) and cytoplasmic (cyt) fractions from HS3018 cells expressing ssTorA–MBP‐scFv13 and ssTorA–MBP–scFv13.R4. Western blots were probed with anti‐c‐myc primary antibody. B. In vitroβ‐galactosidase activity of whole‐cell lysates from E. coli959 cells incubated with purified periplasmic scFv13.R4 targeted through either Sec (ssMBP) or Tat (ssTorA) as an unfused protein (−) or as a fusion to MBP (+). Each sample was assayed in triplicate and data represent the average of three replicate purification and activity experiments.